Immune drug nivolumab takes on returning prostate cancer

NCT ID NCT03637543

Ongoing Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can control the disease by lowering or stabilizing PSA without the cancer spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo)
What this could lead to: If it works, this could point toward a new immune-based treatment option for men with prostate cancer that has returned after initial therapy.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply to all patients. Nivolumab can cause immune-related side effects, and it may not effectively control PSA levels or slow cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
DFCI Londonderry

Londonderry, New Hampshire, 03053, United States
DFCI South Shore

South Weymouth, Massachusetts, 02190, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
St. Elizabeth's Medical Center

Boston, Massachusetts, 02135, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.